Shares of nanocap biotech NextCure (NXTC) surged over 200% in the premarket on Tuesday after the company reached an all-stock merger agreement with Avere. Therapeutics, a privately held biotech focused on inflammatory diseases Concurrently, the companies announced a
Shares of nanocap biotech NextCure (NXTC) surged over 200% in the premarket on Tuesday after the company reached an all-stock merger agreement with Avere.
Therapeutics, a privately held biotech focused on inflammatory diseases
Concurrently, the companies announced a $320M private placement led
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
